CClinicalTrials.gg
CompletedNCT05227781Updated Feb 7, 2022

8 Weeks of L-CIT Supplementation and LIRET on Vascular Function in Hypertensive Postmenopausal Women

An interventional study of L-Citrulline and Placebo in Hypertension and Menopause, sponsored by Texas Tech University. Completed at 1 site in United States. Open to female participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-07.

Sponsored by Texas Tech University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled May 2018, registered Dec 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
Female
01

Study summary

The overall objective of this project is to bring forth evidence that L-Citrulline (L-CIT) supplementation and low intensity resistance exercise training (LIRET) alone and combined will improve vascular function and muscle fitness (mass, strength, and exercise performance) in postmenopausal women with hypertension. The investigators' central hypothesis is that adjuvant L-CIT supplementation may synergistically enhance vascular (arterial stiffness, BP, muscle oxygenation, blood flow) and muscular (strength, exercise performance) responses to LIRET in postmenopausal women with hypertension by improving endothelial vasodilatory function.

Read the detailed description

Individuals who are on medications will refrain from use the morning of all laboratory visits. Participants will be asked to bring medications with them, and will be allowed to ingest it after the vascular measurements have been obtained.

There will be a total of 7 laboratory visits. The 1st visit will be approximately 1 hr and 45 minutes. The 2nd and 3rd visit will be approximately 2 hrs. The 4th and 6th visit will total about 2 hrs and 15 minutes and finally, the 5th and 7th visit will total about 1hr and 15 minutes. This means the total participant time for laboratory visits will be approximately 12 hours. In addition to this, the second 4 weeks of the 8 week study period will involve coming to the Kinesiology and Sport Management building at Texas Tech University main campus 3 times per week to perform the low-intensity resistance training intervention. These visits should last no more than 30-45 minutes.

The first 3 visits will be separated by 48-72 hrs. Visits 3 and 4 will be separated by 4 weeks (first 4 weeks of LCIT or Placebo supplementation). Visits 4 and 5 will be separated by 48-72 hours. Visits 5 and 6 will again be separated by 4 weeks (Second 4 weeks of LCIT or Placebo supplementation with the addition of Low-intensity resistance exercise in both groups).

Approximately 12 hours total for each of the 7 laboratory visits, as well as 30-45 minutes 3 times per week during the last 4 weeks of the 8 week study.

Using a parallel placebo-controlled design, postmenopausal women with elevated blood pressure or hypertension will be randomized to receive L-CIT supplementation (10g/day) alone for 4 weeks, followed by 4 weeks of L-CIT supplementation in combination with low-intensity resistance training or placebo (maltodextrin) alone for 4 weeks, followed by 4 weeks of placebo in combination with low-intensity resistance training.

Differences between conditions (Citrulline vs Placebo) will be analyzed with independent samples t-test. Two-way ANOVA with repeated measures with Bonferroni adjustments will be used to analyze group (CIT vs. PL) by time (baseline, post-supplementation only, supplement + low-intensity resistance exercise training) interactions between the outcome variables. If group-by-time interactions are detected, post-hoc comparisons will be performed via paired or independent t-tests.

02

Conditions studied

  • Hypertension
  • Menopause

Browse trials for

Keywords

  • Endothelial Function
  • Arterial Stiffness
  • Muscle Function
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 29 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Texas Tech University is the lead sponsor of 82 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Women aged 50-75 years
  • Resting systolic BP 120-159 mmHg
  • Sedentary (\< 60 min of exercise/week)
  • Body mass index of 18.5-39.9 kg/m2)
  • Fasting glucose \< 126 mg/dL
  • HbA1c \< 6.4%.

Exclusion criteria

Exclusion Criteria:

  • Body mass index ≥ 40 or \< 18.5 kg/m2
  • Diagnosed with type 1 or 2 diabetes mellitus
  • Cardiovascular diseases
  • Systolic blood pressure > 170 mmHg or on more than two anti-hypertensive medication
  • Other chronic diseases such as cancer, asthma, glaucoma, thyroid, kidney, liver and pancreatic disease
  • Individuals incorporated in a weight loss program and aerobic or resistance training program
  • Heavy smokers (> 20 cigarettes per day)
  • Heavy drinkers (> 12 alcoholic drinks per week)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    L-Citrulline

    L-Citrulline: 10 grams/day

    Dietary Supplement: L-Citrulline

  • Placebo comparator
    Placebo

    Maltodextrin: 10 grams/day

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementL-Citrulline

    8 weeks of L-Citrulline supplementation (10 grams/day)

  • Dietary supplementPlacebo

    8 weeks of Placebo (maltodextrin; 10 grams/day)

06

What researchers measure

Primary outcomes

  1. Changes in endothelial function via brachial artery flow-mediated dilation (effects of L-Citrulline only)

    Endothelial function will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone using brachial artery flow-mediated dilation. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  2. Changes in endothelial function via superficial femoral artery flow-mediated dilation (effects of L-Citrulline only)

    Endothelial function will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone using superficial femoral artery flow-mediated dilation. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  3. Changes in endothelial function via brachial artery flow-mediated dilation (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, endothelial function will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs using brachial artery flow-mediated dilation. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  4. Changes in endothelial function via superficial femoral artery flow-mediated dilation (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, endothelial function will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs using superficial femoral artery flow-mediated dilation. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  5. Changes in arm exercise blood flow (effects of L-Citrulline only)

    Blood flow will be measured in the brachial artery during low intensity arm exercise. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  6. Changes in leg exercise blood flow (effects of L-Citrulline only)

    Blood flow will be measured in the superficial femoral arteries during low intensity leg exercise. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  7. Changes in arm exercise blood flow (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, blood flow will be measured in the brachial artery during low intensity arm exercise. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

  8. Changes in leg exercise blood flow (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, blood flow will be measured in the superficial femoral artery during low intensity leg exercise. All measurements will be performed using Doppler ultrasound.

    Time frame: 4 weeks

Secondary outcomes

  1. Changes in arterial stiffness via arm, leg, and aortic pulse wave velocity (effects of L-Citrulline only)

    Arterial stiffness will be assessed using pulse wave velocity of the arm (carotid-radial), leg (femoral-ankle), and aorta (carotid-femoral) at baseline and after 4 weeks of L-Citrulline supplementation alone using applanation tonometry.

    Time frame: 4 weeks

  2. Changes in arterial stiffness via arm, leg, and aortic pulse wave velocity (effects of L-Citrulline combined with low-intensity resistance exercise training)

    Arterial stiffness will be assessed using pulse wave velocity of the arms (carotid-radial), legs (femoral-ankle), and aorta (carotid femoral) using applanation tonometry after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  3. Changes in aortic hemodynamics using pulse wave analysis (effects of L-Citrulline only)

    The speed and reflection pressures, both representing aortic hemodynamic parameters, will be assessed using radial artery pulses and a validated transfer function (AtCor Medical) at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  4. Changes in aortic hemodynamics using pulse wave analysis (effects of L-Citrulline combined with low-intensity resistance exercise training)

    The speed and reflection pressures, both representing aortic hemodynamic parameters, will be assessed using radial artery pulses and a validated transfer function (AtCor Medical) after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  5. Changes in brachial and aortic blood pressure via automated sphygmomanometry (effects of L-Citrulline only)

    Brachial and aortic blood pressures (systolic and diastolic) will be assessed using an arm cuff at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  6. Changes in brachial and aortic blood pressure via automated sphygmomanometry (effects of L-Citrulline combined with low-intensity resistance exercise training)

    Brachial and aortic blood pressures (systolic and diastolic) will be assessed using an arm cuff after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  7. Changes in muscle strength (effects of L-Citrulline only)

    Handgrip and leg strength (leg press, leg extension, leg flexion, calf raises) will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  8. Changes in muscle strength (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, handgrip and leg strength (leg press, leg extension, leg flexion, calf raises) will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs. These 4 exercises are to be of focus during the training sessions (3 days/week, 12 total training sessions).

    Time frame: 4 weeks

  9. Quantification of L-Arginine (effects of L-Citrulline only)

    Serum levels of L-Arginine (nmol/ul) will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  10. Quantification of Arginase (effects of L-Citrulline only)

    Serum levels ofarginase (pg/mL) will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  11. Quantification of nitric oxide (effects of L-Citrulline only)

    Serum levels ofnitric oxide (umol/L) will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  12. Quantification of Endothelin-1 (effects of L-Citrulline only)

    Serum levels of endothelin-1 (pg/mL) will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  13. Quantification of L-Ornithine (effects of L-Citrulline only)

    Serum levels of L-Ornithine (pmol/ul) will be assessed at baseline and after 4 weeks of L-Citrulline supplementation alone.

    Time frame: 4 weeks

  14. Quantification of L-Arginine (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, serum levels of L-Arginine (nmol/ul) will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  15. Quantification of arginase (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, serum levels of arginase (pg/mL) will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  16. Quantification of nitric oxide (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, serum levels of nitric oxide (umol/L) will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  17. Quantification of endothelin-1 (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, serum levels of endothelin-1 (pg/mL) will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

  18. Quantification of L-Ornithine (effects of L-Citrulline combined with low-intensity resistance exercise training)

    After the 4-week assessment, serum levels of L-Ornithine (pmol/ul) will be assessed after 4 additional weeks of L-Citrulline supplementation with combined low-intensity resistance exercise training with the legs.

    Time frame: 4 weeks

07

Study locations

1 site
  • Texas Tech University
    Lubbock, Texas 79409, United States
08

References and documents

Individual participant data

Plan to share: No — All participants are to be de-identified. Only anthropometric information and data from the outcome variables will be analyzed. All data will be condensed into an SPSS file, which will then be given to Doctoral Students for analysis. This file will be transferred between hard drives, not sent via email. This is done to ensure that all data remains confidential.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05227781
Lead sponsor
Texas Tech University
Responsible party
Arturo Figueroa (Arturo Figueroa, Principal Investigator, Texas Tech University) — Principal investigator
First posted
Feb 7, 2022
Start date
May 24, 2018
Primary completion
Jan 10, 2022
Completion
Jan 10, 2022
Last update
Feb 7, 2022

Study contacts

Arturo Figueroa
principal investigator · Texas Tech University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion